Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 13/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.51 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.49 |
| ▸ | KDM4A | O75164 | 3/20 | 0.49 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4894918 | 0.90 | KDM5A (0.54) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL4896270 | 0.87 | KDM5A (0.44) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL21389643 | 0.85 | KDM5A (0.56) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL4897891 | 0.83 | KDM5A (0.46) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL28307831 | 0.83 | KDM5A (0.66) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL10697365 | 0.81 | KDM5A (0.59) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL2046999 | 0.81 | MMP1 (0.50) | KDM5AKDM4C | |
| SCHEMBL22211259 | 0.79 | KDM5A (0.56) | KDM5AKDM4CPHF8KDM4AKDM5C | |
| SCHEMBL5209063 | 0.79 | EPHX2 (0.46) | KDM5AKDM4CPHF8KDM4ACNR1 | |
| SCHEMBL4889336 | 0.79 | KDM4C (0.50) | KDM5AKDM4CPHF8KDM4AKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC | 2008-08-14 | — | — | US | disclosed |
| EP-1869051-A1 | 4-PIPERAZINYLTHIENO Ý2,3-D¨PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006103545-A1 | 4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFKP, PF4, P2RY4 | KDM5A 3284/4885KDM4C 2349/4885PHF8 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.